Schering-Plough Foot Care Sales Show Modest Growth; Sun Care Plummets
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough's foot care/antifungals business stood alone as the sole producer of positive sales growth within the firm's consumer health stable during the third quarter.
You may also be interested in...
Schering Sun Care Sees Strong Lift In Q4, Playtex Sun Up 11% In 2000
Schering-Plough sun care sales skyrocketed 41% in the fourth quarter to $35 mil., rounding out a seesaw year and helping the company's sun products segment realize an 8% boost in 2000 to $199 mil.
Lamisil AT Spray Pump, Solution Dropper Line Extensions Launching June 1
Novartis Lamisil AT Spray Pump and Solution Dropper, both terbinafine hydrochloride solution 1%, are launching June 1, "just in time for the peak summer athlete's foot season," the firm said. FDA approved the Rx-to-OTC switch March 17. Novartis filed the NDA (21-124) for the topical solution with the agency May 14, 1999.
Schering's Bain de Soleil Purchase Adds Premium Line To Coppertone Stable
Schering-Plough's acquisition of the Bain de Soleil sun care line from Pfizer adds an "established, premium brand" to Schering's sun care portfolio, allowing it "to expand and strengthen" the Coppertone line, Schering announced Oct. 7.